The issue is what is the radiobiological dose rather than the MTD, as we do with the development of drugs, and also we need to take into account the tumor burden. For these reasons alone fix doses do not apply to all patients. These points without taking consideration the purpose of the treatment, meaning palliative or disease control. A fix dose does not fit all. This issue may be less of an issue with alpha particles but still an important one.
Agreed. We need to move towards more advanced (and important) measures, e.g. things like biologically effective dose (BED). Presently we're stuck on fixed injected activity for all, which is far from delivering similar doses. The end, as you say very well, is the clinical task under consideration; e.g. disease control, and for that we need radiobiology.
![Radiopharmaceuticals for Imaging [L11]](http://i.ytimg.com/vi/P7wjj_vcBBc/mqdefault.jpg)
The issue is what is the radiobiological dose rather than the MTD, as we do with the development of drugs, and also we need to take into account the tumor burden. For these reasons alone fix doses do not apply to all patients. These points without taking consideration the purpose of the treatment, meaning palliative or disease control. A fix dose does not fit all. This issue may be less of an issue with alpha particles but still an important one.
Agreed. We need to move towards more advanced (and important) measures, e.g. things like biologically effective dose (BED). Presently we're stuck on fixed injected activity for all, which is far from delivering similar doses. The end, as you say very well, is the clinical task under consideration; e.g. disease control, and for that we need radiobiology.